CHARLOTTESVILLE, VA, UNITED STATES, July 9, 2024 / EINPresswire.com / -- Contraline, a clinical-stage biotechnology company, has announced promising initial safety and efficacy results from its First-in-Human clinical trial. The trial, which is evaluating the safety and preliminary efficacy of Contraline’s ADAM™, a non-permanent male contraceptive, has had its first patients demonstrate 12 months of efficacy in the study.

ADAM™ is a water-soluble, biocompatible, and non-permanent hydrogel that is implanted into the vas deferens where it blocks sperm transport, resulting in azoospermia (no sperm in the ejaculate). ADAM™ has the potential to be the first male contraceptive option beyond condoms (single-use) and vasectomy (permanent).

Earlier this year, Contraline completed enrollment of an open-label, multicenter trial, with 25 participants across three sites in Australia. ADAM™ continues to demonstrate a favorable safety profile, with no reports of treatment-related serious adverse events. All adverse events (AEs) have been anticipated and a majority of the AEs have been mild. Additionally, no AEs have been related to ADAM™ hydrogel.